{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:50:58Z","timestamp":1782773458277,"version":"3.54.5"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ascites formation is a sign of decompensation of cirrhosis and heralds a poor prognosis. The widely used standard binary classification of ascites as diuretic\u2010responsive or refractory does not cover the spectrum of ascites and has limited prognostic information. We developed the Cirrhotic Ascites Severity (CIRAS) model to predict 1\u2010year mortality among 465 patients randomized to placebo in the satavaptan trials investigating treatment of cirrhotic ascites. We used multivariable logistic regression to derive the CIRAS model based on these variables: ascites discomfort score (\u226450 or &gt;50), plasma sodium (\u2265140, 133\u2013139, 125\u2013132, or &lt;125\u2009mmoL\/L), and a composite of ascites accumulation and diuretic treatment. We validated the prediction model in 697 trial participants randomized to satavaptan treatment. The 1\u2010year all\u2010cause mortality was 19.6%. The area under the receiver operator curve was higher for the CIRAS model than for the standard ascites classification into refractory and diuretic\u2010responsive in both the development cohort (0.68 [95% confidence interval (CI): 0.62\u20130.75] vs. 0.62 [0.57\u20130.68]), and the validation cohort (0.68 [0.64\u20130.72] vs. 0.55 [0.51\u20130.60]). The CIRAS model had similar discrimination to the Child\u2010Pugh score and nearly as good as the Model for End\u2010Stage Liver Disease (MELD), MELD\u2010Na, and MELD 3.0. <jats:italic toggle=\"yes\">Conclusions<\/jats:italic>: The CIRAS model based on simple ascites\u2010relevant data is an easily applicable and patient\u2010centered way to describe the severity and prognosis of all ascites grades. It carries more prognostic information than today's label of \u201crefractory ascites\u201d and forms the basis for earlier and better clinical decisions related to ascites management.<\/jats:p>","DOI":"10.1002\/hep4.2065","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T13:44:33Z","timestamp":1660657473000},"page":"3175-3185","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Development and validation of the Cirrhotic Ascites Severity model\u2014A patient\u2010reported outcome\u2010based model to predict 1\u2010year mortality"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-6539","authenticated-orcid":false,"given":"Rasmus Hvidbjerg","family":"Gantzel","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Department of Clinical Medicine,Aarhus University,Aarhus,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Kristian","family":"Aagaard","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Department of Clinical Medicine,Aarhus University,Aarhus,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Vilstrup","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Department of Clinical Medicine,Aarhus University,Aarhus,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-3158","authenticated-orcid":false,"given":"Hugh","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Antiviral Research Unit,Evotec ID,Lyon,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-7910","authenticated-orcid":false,"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Department of Clinical Medicine,Aarhus University,Aarhus,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-1430","authenticated-orcid":false,"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Aarhus University Hospital,Aarhus N,Denmark"},{"name":"Department of Clinical Medicine,Aarhus University,Aarhus,Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"hep42065-bib-0001-20241104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: natural history and prognostic factors","volume":"7","year":"1987","journal-title":"Hepatology"},{"key":"hep42065-bib-0002-20241104","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Management of cirrhosis and ascites","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"hep42065-bib-0003-20241104","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep42065-bib-0004-20241104","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"hep42065-bib-0005-20241104","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cgh.2020.03.065","article-title":"Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep42065-bib-0006-20241104","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep42065-bib-0007-20241104","first-page":"108","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","year":"2011","journal-title":"Gut"},{"key":"hep42065-bib-0008-20241104","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep42065-bib-0009-20241104","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Nonselective \u03b2\u2010blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patients","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep42065-bib-0010-20241104","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep42065-bib-0011-20241104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apt.15084","article-title":"Quality of life measures predict mortality in patients with cirrhosis and severe ascites","volume":"49","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"hep42065-bib-0012-20241104","first-page":"514","article-title":"Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients","volume":"88","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"hep42065-bib-0013-20241104","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1478-3231.2004.0991.x","article-title":"Clinical characteristics and outcome of patients with cirrhosis and refractory ascites","volume":"24","year":"2004","journal-title":"Liver Int"},{"key":"hep42065-bib-0014-20241104","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.15882","article-title":"MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites","volume":"52","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"hep42065-bib-0015-20241104","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","year":"1973","journal-title":"Br J Surg"},{"key":"hep42065-bib-0016-20241104","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","year":"2000","journal-title":"Hepatology"},{"key":"hep42065-bib-0017-20241104","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","article-title":"MELD 3.0: the model for end\u2010stage liver disease updated for the modern era","volume":"161","year":"2021","journal-title":"Gastroenterology"},{"key":"hep42065-bib-0018-20241104","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2012.03.018","article-title":"Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites","volume":"57","year":"2012","journal-title":"J Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:00:55Z","timestamp":1730707255000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2065","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"2022-07-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}